HPV E6 Inhibitor Program
HPV-driven Cancers (e.g., Cervical, Oropharyngeal)
Key Facts
About Kovina Therapeutics
Kovina Therapeutics is pioneering a novel antiviral approach to address the significant unmet medical need in HPV-associated diseases, from precancerous lesions to invasive cancers. Its core technology involves small molecules that selectively inactivate the HPV E6 oncoprotein, triggering apoptosis in infected cells while sparing healthy tissue. The company is backed by NIH grants and a seasoned leadership team, positioning it to develop a non-surgical treatment option for a global patient population underserved by current vaccines and standard therapies.
View full company profileAbout Kovina Therapeutics
Kovina Therapeutics is pioneering a novel antiviral approach to address the significant unmet medical need in HPV-associated diseases, from precancerous lesions to invasive cancers. Its core technology involves small molecules that selectively inactivate the HPV E6 oncoprotein, triggering apoptosis in infected cells while sparing healthy tissue. The company is backed by NIH grants and a seasoned leadership team, positioning it to develop a non-surgical treatment option for a global patient population underserved by current vaccines and standard therapies.
View full company profile